Medical News

RSS

GE Healthcare to present anti-[18F]FACBC phase 1 study results at Society of Nuclear Medicine annual meeting

GE Healthcare, a unit of the General Electric Company, today will present results of a phase 1 study of anti-[18F]FACBC at the 57th annual meeting of the Society of Nuclear Medicine in Salt Lake City, Utah. The presentation closely follows the launch of the phase 2 clinical development program for anti-[18F]FACBC, which was initially discovered and developed by Emory University, Atlanta, Georgia, and was licensed to Nihon Medi-Physics Co., Ltd. (NMP) of Japan.

9 Jun 2010

VARI researchers identify enzyme that could help diagnose and treat cholangiocarcinoma

In collaboration with the National Cancer Centre, Singapore, Van Andel Research Institute researchers have identified an enzyme that could help diagnose and treat cholangiocarcinoma, a form of liver cancer that strikes up to 3,000 new patients each year in the United States.

9 Jun 2010

Merck's MK-4305 improves overall sleep efficiency in primary insomnia patients

Clinical results from a Phase IIb study showed that MK-4305, Merck's investigational dual orexin receptor antagonist, was significantly more effective than placebo (p<0.005) in improving overall sleep efficiency at night one and at the end of week four in patients with primary insomnia. MK-4305 was generally well-tolerated in the study. Orexins are neuropeptides (chemical messengers) that are released by specialized neurons in the hypothalamus region of the brain and are believed to be an important regulator of the brain's sleep-wake process.

9 Jun 2010

Better understanding of eye movements can help develop strategies for reducing crash risks: Study

More than 16 people are killed and more than 1,300 people are injured each day in crashes involving a distracted driver, a phenomenon that could be reduced with the right application of motion information and appropriate eye movements.

9 Jun 2010

Pharnext closes €4.8-million Series A funding round

Pharnext SAS, a biopharmaceutical company specializing in the development of innovative treatments based on Pleotherapy™ for severe neurological diseases, today announced that it had closed a €4.8-million Series A round of funding on June 3rd (corresponding to a company valuation of €45 million).

9 Jun 2010

Short people at greater risk of developing CVD or CHD compared to tall people: Review

Short people are at greater risk of developing heart disease than tall people, according to the first systematic review and meta-analysis of all the available evidence, which is published online today (Wednesday 9 June) in the European Heart Journal.

9 Jun 2010

Lytix Biopharma, KAEL-GemVax granted approval for GV1001/LTX-315 combination cancer therapy study

The Norwegian biopharmaceutical company Lytix Biopharma and Korean company KAEL-GemVax today announced approval by the Norwegian Medicines Agency ('Statens Legemiddelverk') to test a combination of LTX-315 and GV1001 as vaccine therapy in patients with resected tumours. Lytix Biopharma CEO Gunnar Salid states, "We are delighted to announce the approval of our joint study to test a combination of two very interesting experimental drugs.

9 Jun 2010

RoundTable signs agreement to acquire Ophthalmic Systems business unit

RoundTable Healthcare Partners, an operating-oriented private equity firm focused exclusively on the health-care industry, announced today that is has entered into an agreement with BD to acquire the Ophthalmic Systems unit, a business within the BD Medical segment. BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents.

9 Jun 2010

Pelosi releases statement on the benefits of Affordable Care Act for America's seniors

Speaker Nancy Pelosi today released the following statement on the benefits of the Affordable Care Act for America's seniors. President Obama held a tele-town hall with seniors in Wheaton, Md. today on the legislation's provisions to strengthen Medicare, close the 'donut hole,' and protect seniors from fraud.

9 Jun 2010

Helix BioPharma reports Phase II clinical results of Topical Interferon Alpha-2b for ano-genital warts

Helix BioPharma Corp. today announced results from the Phase II clinical trial assessing the efficacy and safety of Topical Interferon Alpha-2b cream for the treatment of ano-genital warts (AGW).

9 Jun 2010

Ontario's Community Pharmacies Coalition reacts to new regulations and vows to fight for patient care

Ontario's Community Pharmacies Coalition are extremely disappointed by yesterday's announcement by Health Minister Deb Matthews and the posting of amendments to regulations under the OBDA and DIDFA as it all but assures that Ontario patients will be less able to freely access the front-line community healthcare they have come to rely on.

9 Jun 2010

Harvard and University of Montreal researchers challenge views on how cells respond to stimuli

People have them, cats have them and whales have some, too. Neurons, those interlinked nerve cells that carry sensations including pain, stretch from our spinal cords to the tips of our toes, paws or fins. According to a new study published in the journal Cell, scientists from the Harvard Medical School, the University of Montreal and the Dana-Farber Cancer Institute have found a new way by which nerve cells relay information that tell them to grow from millimeters to meters in length.

9 Jun 2010

IBM, ProtonMedia enter teaming agreement for 3-D virtual collaboration platform

IBM and ProtonMedia have entered into a teaming agreement that will result in the delivery of innovative, 3-D virtual collaboration and communication solutions engineered specifically for global life sciences organizations. Under the terms of the agreement, ProtonMedia's ProtoSphere technology will be the basis for customized, 3-D virtual collaboration environments to create high-performance workplaces.

9 Jun 2010

Research findings hold promise for debilitating emotional symptoms of FXS

The study, which appears in the journal the Proceedings of the National Academy of Sciences, is also of potential therapeutic significance-it showed that a brief pharmacological treatment is capable of correcting some of these synaptic deficits in mice genetically engineered to model FXS.

9 Jun 2010

Experimental drug ipilimumab increases overall survival in patients with metastatic melanoma: Study

The Melanoma Network of Canada is excited with the new hope that long-anticipated results of a late-stage skin cancer trial brings to patients with advanced melanoma. The results, presented at the American Society of Clinical Oncology annual meeting, show increased survival with the experimental treatment ipilimumab in patients with previously-treated metastatic melanoma, the most deadly form of skin cancer.

9 Jun 2010

CPAP therapy effective at recouping memory abilities impaired by obstructive sleep apnea

Continuous positive airway pressure therapy helps restore memory consolidation in adults with obstructive sleep apnea, suggests a research abstract that will be presented Wednesday, June 9, 2010, in San Antonio, Texas, at SLEEP 2010, the 24th annual meeting of the Associated Professional Sleep Societies LLC.

9 Jun 2010

LAB Research completes exclusive radiotherapy partnership with DMV

LAB Research Inc., a Canadian-based global non-clinical contract research organization, today announced that it has completed an exclusive radiotherapy partnership with DMV Veterinary Centre creating a dedicated research platform.

9 Jun 2010

Discovery Labs receives FDA guidance to gain Surfaxin approval for RDS in premature infants

Discovery Laboratories, Inc. announces today that it has received written guidance from the U.S. Food and Drug Administration (FDA) that is consistent with its ongoing, comprehensive preclinical program to resolve the sole remaining chemistry, manufacturing & control (CMC) issue necessary to potentially gain FDA marketing approval for Surfaxin® (lucinactant) for the prevention of Respiratory Distress Syndrome (RDS) in premature infants.

9 Jun 2010

Psychological intervention program teaches breast cancer patients how to cope with the disease

A psychological intervention program designed for breast cancer patients reduces the risk of dying if the cancer recurs, new research shows. The study is the latest in a series at Ohio State University that have shown that an intervention program that teaches patients how to cope with the disease can boost their health, well-being and even their chances of survival.

9 Jun 2010

Fluidigm develops world's first reusable bio-chip architecture

Fluidigm Corporation today announced it has developed the world's first reusable bio-chip architecture for the commercial market. These reusable integrated fluidic circuits (IFCs) will dramatically lower SNP genotyping costs and are designed to support accelerated sample throughput, while maintaining data quality of 99.75 percent or greater accuracy and 99 percent or greater call rates.

9 Jun 2010

Medical News

GE Healthcare to present anti-[18F]FACBC phase 1 study results at Society of Nuclear Medicine annual meeting

VARI researchers identify enzyme that could help diagnose and treat cholangiocarcinoma

Merck's MK-4305 improves overall sleep efficiency in primary insomnia patients

Better understanding of eye movements can help develop strategies for reducing crash risks: Study

Pharnext closes €4.8-million Series A funding round

Short people at greater risk of developing CVD or CHD compared to tall people: Review

Lytix Biopharma, KAEL-GemVax granted approval for GV1001/LTX-315 combination cancer therapy study

RoundTable signs agreement to acquire Ophthalmic Systems business unit

Pelosi releases statement on the benefits of Affordable Care Act for America's seniors

Helix BioPharma reports Phase II clinical results of Topical Interferon Alpha-2b for ano-genital warts

Ontario's Community Pharmacies Coalition reacts to new regulations and vows to fight for patient care

Harvard and University of Montreal researchers challenge views on how cells respond to stimuli

IBM, ProtonMedia enter teaming agreement for 3-D virtual collaboration platform

Research findings hold promise for debilitating emotional symptoms of FXS

Experimental drug ipilimumab increases overall survival in patients with metastatic melanoma: Study

CPAP therapy effective at recouping memory abilities impaired by obstructive sleep apnea

LAB Research completes exclusive radiotherapy partnership with DMV

Discovery Labs receives FDA guidance to gain Surfaxin approval for RDS in premature infants

Psychological intervention program teaches breast cancer patients how to cope with the disease

Fluidigm develops world's first reusable bio-chip architecture

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Latest News